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AbstrAct
Introduction Individual cohort studies in various populations 
and study-level meta-analyses have shown interarm 
differences (IAD) in blood pressure to be associated with 
increased cardiovascular and all-cause mortality. However, 
key questions remain, such as follows: (1) What is the 
additional contribution of IAD to prognostic risk estimation 
for cardiovascular and all-cause mortality? (2) What is the 
minimum cut-off value for IAD that defines elevated risk? (3) 
Is there a prognostic value of IAD and do different methods of 
IAD measurement impact on the prognostic value of IAD? We 
aim to address these questions by conducting an individual 
patient data (IPD) meta-analysis.
Methods and analysis This study will identify prospective 
cohort studies that measured blood pressure in both arms 
during recruitment, and invite authors to contribute IPD 
datasets to this collaboration. All patient data received will be 
combined into a single dataset. Using one 
-stage meta-analysis, we will undertake multivariable time-
to-event regression modelling, with the aim of developing a 
new prognostic model for cardiovascular risk estimation that 
includes IAD. We will explore variations in risk contribution 
of IAD across predefined population subgroups (eg, 
hypertensives, diabetics), establish the lower limit of IAD that 
is associated with additional cardiovascular risk and assess 
the impact of different methods of IAD measurement on risk 
prediction.
Ethics and dissemination This study will not include any 
patient identifiable data. Included datasets will already have 
ethical approval and consent from their sponsors. Findings 
will be presented to international conferences and published 
in peer reviewed journals, and we have a comprehensive 
dissemination strategy in place with integrated patient and 
public involvement.
PROSPERO registration number CRD42015031227.
IntroductIon
Cardiovascular disease (CVD) is the leading 
cause of death worldwide. Elevated blood 
pressure (BP) is the main global risk factor 
for premature morbidity and mortality, and 
the prevalence of hypertensive heart disease is 
not declining over time.1 2 Control of high BP 
is therefore fundamental in the prevention of 
CVD.3 Prevention of CVD is promoted by the 
UK Quality and Outcomes Framework, within 
which BP control is a key indicator,3 and BP 
measurement is a common reason for consul-
tation in primary care.4 Although the benefits 
of treatment in hypertension are greatest for 
individuals at the highest estimated risk,5 the 
majority of events occur in those at low to 
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Protocol
Strengths and limitations of this study
 ► This individual participant data (IPD) meta-analysis 
brings together the largest dataset yet assembled 
to study the association of interarm blood pressure 
differences with mortality and morbidity.
 ► IPD permits a consistent approach to all of the 
available data that cannot be achieved with study-
level meta-analyses. It maximises statistical 
power to allow a full exploration of the prognostic 
association between interarm differences and time-
to-event outcomes.
 ► Patient and public involvement is embedded at 
every step of this study.
 ► Inclusion of cohorts from around the world will 
maximise the ability to generalise our findings.
 ► We will have sufficient data to explore subgroup 
and sensitivity analyses addressing questions that 
cannot be answered at individual study level or 
through aggregated meta-analyses.
 ► Data collection, including methods of blood pressure 
measurement, varies between cohorts and is an 
acknowedged limitation of the data; this will be 
addressed in planned senstivity analyses.
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medium risk.6 Therefore, recognition of novel CVD risk 
markers to refine risk prediction and stratify treatment 
priorities is important.7 8
A systolic BP difference between arms (interarm differ-
ence, IAD) is one risk marker that is easily measured 
clinically with no additional equipment. Differences 
between arms can cause errors in BP interpretation and 
management when not recognised.9–13 A systolic IAD is 
regularly encountered in clinical practice: in community 
settings, differences ≥10 mm Hg in systolic pressures are 
seen in 11.2% (95% CI: 9.1% to 13.6%) of hypertensive 
subjects, 7.4% (5.8% to 9.2%) of people with diabetes and 
3.6% (2.3% to 5.0%) of the general population.14 Preva-
lence rates are higher in outpatient and hospital settings;15 
thus, questions about the importance of a finding of IAD 
frequently arise.16 Recommendations to initially check BP 
in both arms are included in international hypertension 
guidelines,17–21 but may not followed by the majority of 
clinicians,22 23 including UK general practitioners, due to a 
lack of clarity as to the importance of detecting an IAD.24 25
IAD can cause errors in BP interpretation and manage-
ment when not recognised, thus exposing individuals 
to avoidable risk through suboptimal BP control.9–13 
In individual studies, systolic IADs are associated in 
cross-sectional analyses with greater prevalence of 
CVD,26 27 peripheral arterial disease,28 cerebrovascular 
disease,28 29 diabetes30–32 and hypertension.32 33 Study-
level meta-analyses, however, disagree concerning 
associations in hypertension and diabetes.15 16 IADs are 
also independently associated with increased left ventric-
ular mass,34 arterial stiffness30 34 35 and in diabetes with 
nephropathy31 36 and retinopathy.31 Recent data suggest 
that IAD may also be associated prospectively with greater 
cognitive decline.37 38
Prospectively, systolic IADs are associated with elevated 
cardiovascular and all-cause mortality, and with increased 
CVD event rates.29 31 32 39–46 Evidence for this association 
is derived from a number of cohort studies and our 2012 
meta-analysis of study-level aggregate data.28 Since our 
systematic review and meta-analysis, several new large 
cohort studies have been published that include patients 
with diabetes, those at CVD risk and general populations. 
We and others have updated study-level analyses to include 
these;47 48 however, this approach is limited in the conclu-
sions that can be drawn, because it combines studies with 
different patient characteristics, different methodolog-
ical choices (eg, in choice of cut-off values for IAD) and 
different analytical approaches. By obtaining the original 
individual participant data (IPD) from these cohorts, a 
consistent approach to all of the data will, for the first 
time, provide the necessary information and maximise 
statistical power to allow a full exploration of the prog-
nostic association between systolic IAD and time-to-event 
outcomes across populations of differing baseline CVD 
risk, and allow adjustment for important confounders in 
a standardised manner.
This study will undertake an IPD meta-analysis to 
address the following research questions.
What Is the addItIonal contrIbutIon of systolIc Iad 
to prognostIc rIsk estImatIon for cardIovascular 
fatal and non-fatal events, and all-cause 
mortalIty?
By taking account of a systolic IAD, the precision of cardio-
vascular risk prediction is increased when compared with 
that achieved by using the Framingham model alone,42 46 
in a similar manner to that shown for the ankle–brachial 
index.49 However, individual studies use different models 
of adjustment for other known cardiovascular risk factors, 
which limits our ability to definitively address this question 
with aggregate study-level data alone. HRs associated with 
systolic IADs are greater in cohorts with high background 
CVD risk in comparison with cohorts representative of 
primary care populations,48 50 suggesting that the prog-
nostic contribution of systolic IAD to risk prediction 
varies with underlying population cardiovascular risk.
What Is the cut-off value for Iad that defInes 
elevated rIsk and Is there a relatIonshIp betWeen 
IncreasIng Iad and IncreasIng rIsk?
Survival differences have been demonstrated for systolic 
IADs ≥5, 10 and 15 mm Hg,43 45 but no consistent rela-
tionship between higher systolic IADs and greater HRs 
has yet emerged.47 48 Consequently, uncertainty remains 
as to the appropriate cut-off level of systolic IAD for risk 
prediction.28 41 51 Further investigation is required to 
determine what, if any, systolic or diastolic IAD cut-off can 
be regarded as clinically important.
do dIfferent methods of Iad measurement 
have an Impact on the prognostIc value of Iad 
measurements?
In clinical practice, most people measure IAD sequen-
tially because they only have access to one single-cuff BP 
measurement device. There are some data suggesting that 
simultaneous measurement of both arms at once is more 
accurate, in prognostic terms, than sequential measure-
ment.52 53 This project will evaluate whether different 
measurement methods influence the prognostic impact 
of IAD, and inform the future recommendations for the 
measurement of IAD.
methods and analysIs
aims and objectives
This IPD meta-analysis has the following aims.
1. To undertake an updated systematic review with 
comprehensive literature searches to identify any 
hitherto unknown potentially eligible relevant IAD 
datasets and invite their chief investigators to join the 
collaboration. Searches will run and be updated to 
January 2017.
2. To standardise and combine IPD from prospective 
observational cohorts that measured BP in both 
arms during patient recruitment, and which 
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collected morbidity and mortality outcomes in adult 
populations.
3. To develop overarching (across studies) multivariable 
time-to-event models for all-cause mortality, CVD 
mortality, non-fatal CVD events, risk for fatal and/
or non-fatal cardiovascular events, and for all-cause 
mortality, to establish any additional contribution of 
systolic IAD to risk prediction. We aim to use these 
results in inform the development of a new prognostic 
model of CVD risk estimation that takes account of 
systolic IAD.
4. To examine the prospective univariable and 
multivariable associations of systolic IAD with any 
change in cognitive function.
5. Explore any additional risk contribution of systolic 
IAD across predefined subgroups based on underlying 
health status (ie, with or without existing CVD, 
diabetes or hypertension), when adjusted for major 
confounders such as gender, age or ethnicity.
6. Explore the lower limit of magnitude for a systolic 
IAD, at which the IAD adds significantly to the risk 
prediction model, to define a clinically important cut-
off value for IAD based on prognostic value.
7. Undertake a subgroup analysis by method of IAD 
measurement (ie, sequentially vs simultaneously 
measured BPs) to explore any effect of different 
methods on risk prediction by IAD.
8. Undertake cross-sectional analyses to describe the 
epidemiology of IAD in the dataset. We will look for 
variations in the prevalence of IAD by age, gender 
and ethnicity, and we will describe the risk factors or 
disease conditions associated with the presence of 
an IAD. This information can inform guidance as to 
whom we should assess for the possible presence of 
IAD in the future.
search strategy for identification of studies
Relevant electronic databases (Medline, Old Medline, 
Medline in Process, Embase and CINAHL) will be 
searched for all articles published since their respective 
start dates that potentially meet the inclusion criteria 
(see online appendix: Medline search strategy). The 
search strategy will be verified through scoping searches 
checking for inclusion of all potentially relevant cohorts 
already known to the authors. Searches will be augmented 
by contacts with authors active in the field, and by dissem-
ination of our interest through established cardiovascular 
intervention collaborations. Regular update searches will 
be run during the project.
eligibility criteria for studies
Studies will be eligible for inclusion in the IPD dataset if 
they meet the following criteria.
 ► Design: prospective cohort studies.
 ► Population: adults aged 18 or over, with or without 
existing CVD, with a record of BP in both arms at 
recruitment. BP must have been measured in both 
arms during the same assessment but datasets based 
on either simultaneous or sequential methods of 
measurement will be included.
 ► Setting: community or primary care cohorts or (to 
account for varied healthcare systems) based in 
hospital clinic settings relevant to a wider population, 
for example, unselected diabetes or hypertension 
cohorts. Selected secondary or tertiary care cohorts 
such as those with renal disease or attending vascular 
disease clinics will be excluded.
 ► Sample size: no minimum sample size will be defined.
 ► Publication language and date: no restriction.
 ► Outcome: CVD mortality or all-cause mortality, fatal 
and non-fatal CVD events, or measures of cognitive 
decline.
assessment
Study selections will be undertaken by two authors inde-
pendently. Disagreements will be resolved by discussion 
when possible, and failing that adjudication from the 
remaining reviewing authors will be sought. The quality 
of included cohorts will also be assessed using the Quality 
Improvement in Prognostic Studies (QUIPS) tool.54
data collection
We will ask study authors to provide the following data (if 
available):
Study-level descriptive data
 ► Setting: community, primary care or hospital cohort.
 ► Population: selected, for example hypertension, or 
general.
 ► Method of BP measurement: monitor used, number 
of readings, position (seated or supine).
 ► Method of BP and IAD measurement: sequential or 
simultaneous; any rounding of readings.
Participant-level descriptive data
 ► Demographic details: age, sex, ethnicity, height and 
weight (or body mass index), dominant hand.
 ► Geographical location of partcipants.
 ► Medical history: specifically of cardiovascular or 
peripheral arterial disease, cerebrovascular disease, 
cardiac arrhythmias (diabetes or chronic kidney 
disease).
 ► Smoking history.
 ► Medications prescribed at baseline.
 ► Individual baseline BP readings for each arm and 
heart rate (or means if individual readings are not 
available).
 ► Biochemical measurements: glucose or glycosylated 
haemoglobin, total and high density lipoprotein 
(HDL) cholesterol (fasting or non-fasting), estimated 
glomerular filtration rate, creatine and uric acid.
 ► Measures of CVD risk: for example, Framingham 
score, Qrisk2 score.55 56
 ► Ankle–brachial index.
 ► Any measures or scores reporting deprivation.
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 ► Any baseline measures of cognition, for example, 
Mini Mental State Examination.
 ► Highest level of educational attainment.
Participant-level outcome data
 ► We will seek the number and timings of the following 
events: all-cause deaths, cardiovascular deaths, non-
fatal cardiovascular events, any outcome assessments 
of cognition.
data transfer and cleaning
Data will be transferred by the study teams in line with 
University of Exeter Standard Operating Procedures 
covering electronic transfer.57
On successful transfer, the data will be imported into 
Microsoft SQL server as a table or table set per study for 
cleaning. We are requesting that data are anonymised 
before transfer; should this not happen, anonymisation 
will occur before the backup run (midnight) on the day 
of import to prevent identifiable information entering 
the backup sets and requiring further action. The table/
table sets for each study will remain separate throughout 
the cleaning process, maintaining data integrity prior to 
combining the study-level datasets, and will be versioned 
so a history of the cleaning operations can be reviewed as 
needed, in co-ordination with the statistician.
Finally, the datasets will be joined into a single live 
view/table for statistical analysis, preferably via direct 
connection of a statistical software package to SQL server, 
though static exported files can also be created.
Access to data at all stages of cleaning and analysis will 
be restricted to specific members of staff and secured 
via permissions-dependant user logins, and again follow 
the Standard Operating Procedures if export/transfer 
outside of the SQL server system is required.
statistical analysis
Descriptive analysis and data checking
Study-level data on study and patient characteristics of 
included IPD studies will be summarised in detail, and 
compared with data published in the original study publi-
cation, if available. Comparison with study and patient 
characteristics (where available) of cohort studies that do 
not contribute data to the IPD analysis will be made to 
descriptively assess study inclusion bias.
IAD will be calculated as the absolute difference 
between systolic BP in the right and left arms. If multiple 
values for BP are provided, the mean of the observations 
will be used. For each study, the mean IAD and propor-
tions of patients with an IAD equal to or exceeding 
the three commonly reported cut-off values (5, 10 and 
15 mm Hg) will be reported. We will note the number of 
studies that include the necessary variables for calculation 
of Framingham,55 QRisk256 and other scores as emerge 
from the literature searches. If necessary, we will stan-
dardise covariates that vary across individual studies to 
permit incorporation of that data across studies.
Individual patient data meta-analysis
The outcomes to be investigated are (1) time to CVD 
mortality; (2) time to all-cause mortality; and (3) time to 
CVD morbidity. All analyses will be performed for each 
of these three outcome variables. We will undertake 
both one-stage and two-stage meta-analyses as follows; 
however, the focus will be on the one-stage meta-anal-
ysis. Initial two-stage models will be performed using 
combined data from all datasets, for all outcomes at 3, 
5 and 10-year follow-up cut-off points, using study-level 
outcomes adjustment for baseline systolic BP, age and 
gender. Such models will be used for comparison with the 
results of equivalent one-stage models, and to estimate 
the I-squared heterogeneity statistic.58 59
For the one-stage models, we will non-randomly select 
a subset of the datasets available to act as a validation 
dataset; the selected datasets will include participants 
of both genders and a range of ages.60 To account for 
likely statistical heterogeneity of the datasets (investi-
gated by two-stage models), we anticipate using random 
effects time to event analysis methods. We will aim to 
use random effects methods with a flexible parametric 
survival model.61 62 Alternative parametric models will 
be considered if the dataset is amenable to such models. 
An initial series of models will investigate the associ-
ation between IAD and outcome; IAD will be included 
as a random effect (allowed to vary within study) in all 
models, and all models will include individual study as a 
fixed effect. A series of models will investigate whether 
other patient-level covariates are also significant predic-
tors of outcome, with inclusion of IAD within the model. 
Each individual covariate will be investigated by inclu-
sion as a fixed effect in each model with only IAD and 
study. In a further model, all covariates will be included. 
Any covariates that are statistically significant (at the 
p<0.1 threshold) will be included in a further model, 
and only those with a p value<0.05 will be included in the 
model. Each non-included covariate will then be included 
individually to identify whether addition of the covariate 
improves model fit. This process will allow us to develop 
a model that maximises goodness of fit with the fewest 
statistically significant covariates. This model will be 
compared with the Framingham set of covariates (essen-
tial covariates; table 1). If the models include different 
covariates, we will compare the goodness of fit for our 
model with that of the Framingham model. We will also 
repeat this approach with the inclusion of study-level 
covariates (setting, method of measurement, temporal 
sequence of measurement, geographical region). The 
Akaike Information Criterion63 will be used to assist in 
model selection.
A series of models will then be performed using 
binarised IAD, with cut-off points ranging from 0 to 
20 mm Hg, with increments of 1 mm Hg.64 65 The set of 
covariates previously derived will be used with the aim of 
establishing a cut-off point at which IAD becomes a signif-
icant predictor of risk.
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A further issue of interest is whether there are any 
differential effects of IAD across different patient-level 
characteristics, for example, age, gender and baseline 
systolic BP. To investigate possible differential effects, 
we will perform a series of models, using the model 
including significant predictors previously developed. 
Each model will include the specified covariate and its 
interaction term with IAD, as well as the other patient-
level characteristics. Interactions will be considered 
significant at the p value<0.05, and interpreted in the 
light of multiple testing, although we acknowledge that 
power to detect interaction terms will be limited. We 
will also investigate whether the effect of IAD varies 
with time by including an interaction between time 
and IAD. Finally, we will investigate whether there is 
an interaction effect between measurement method of 
IAD (simultaneous or sequential) and IAD by adding 
measurement method and its interaction with IAD 
into the model including all significant predictors of 
outcome. We will use appropriate centring of variables 
within each study for the interaction models.
Missing data
The percentage of individual participant missing data 
will be reported for each study and participant-level 
covariate. Baseline covariates will be included in the 
modelling if the covariate has at least 50% data present 
in at least three studies.66 Imputation of participant-level 
missing baseline data across the whole dataset will be 
performed; the imputation model will take account of 
individual study. The effect of inclusion of imputed data 
will be checked using a fixed effect model including 
only the imputed covariate (as well as IAD). Analyses 
including imputed data will be considered as sensitivity 
analyses only. The number of studies with study-level 
missing baseline data (ie, no data for a specified vari-
able was collected within the study) will be reported for 
each variable. The course of action of imputing missing 
data at the study level will be considered should the 
number of studies with study-level missing baseline data 
be substantive for individual covariates.
Model validation
The final model will be validated using the calibration 
slope method,67 and internal–external cross validation 
analysis.68 69 Should the prognostic model be found 
to perform poorly for any outcome, we will consider 
possible reasons for such poor performance. It may be 
appropriate to develop a model that is applicable only to 
a subset of studies, for example, including studies from 
the same clinical setting or in similar patient populations.
Incorporation of IAD into a prognostic model based on the 
Framingham score
We will aim to incorporate IAD (if found to be a signifi-
cant prognostic factor for mortality/morbidity) into the 
Framingham scoring system for predicting cardiovas-
cular risk. This model will be developed using the overall 
dataset including all studies that include the Framingham 
covariates. Calibration slopes comparing the observed 
and expected survival probabilities at different time 
points will be calculated, and combined in a two-stage 
meta-analysis for each approach. The pooled estimates 
from these models will be used to compare the calibra-
tion for each model.
Publication and inclusion bias
We will undertake two-stage analyses to compare aggre-
gate level data from contributing and non-contributing 
datasets to test for selection bias. We will qualitatively 
assess inclusion bias by comparing study-level data on 
key variables (eg, age, gender and BP) for cohorts that 
meet our inclusion criteria but for which consent to share 
data is not obtained, with our IPD dataset. We will also 
check whether our collection of studies may be affected 
by publication bias using a funnel plot and Egger’s test for 
each of the outcome variables to confirm asymmetry.70 71
Quality assessment
We will assess individual study quality using the QUIPS 
tool.54 Based on the variation in quality observed, we 
will consider restriction of the models to higher quality 
studies, using criteria to be determined.
patIent and publIc Involvement
The development of this protocol has had considerable 
patient and public involvement (PPI) input. Prior to 
funding, a draft was reviewed by three separate user involve-
ment groups improving the overall clarity in general, and 
in specific areas such as focussing the research questions 
on aspects of IAD that interest users. We convened two 
prefunding public workshops to raise awareness about 
involvement in systematic reviews and gain critical feedback 
for the project. This feedback resulted in a clearer defini-
tion of the population being studied, greater clarity about 
benefits for patients and reinforcement of our user dissem-
ination plans.
We have established a PPI group, specifically for the 
project, who will play an important role in shaping 
the research by taking part in the bimonthly manage-
ment meetings. The group has contributed towards the 
drafting of the protocol. We plan two key workshops to 
ensure that the review findings reach the end user in an 
accessible way. First, a summary writing workshop with the 
PPI group to achieve a clear plain language summary and 
to coproduce a dissemination plan targeted at patients 
and the public. Second, we will convene a larger public 
event on the subject of understanding cardiovascular 
risk, within which the findings of this research can be 
presented in context.
ethIcs and dIssemInatIon
This is a secondary analysis of patient anonymised data. 
All data will have been obtained from studies where 
patients will have already given their consent and approval 
to participate. We will seek written permission for use of 
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individual patient data from each individual study lead 
investigator. We will therefore not seek no further ethical 
approval.
The study will be reported in accordance with the 
Preferred Reporting Items for a Systematic Reviewand 
Meta-analysis of Individual Participant Data (PRIS-
MA-IPD) statement.72 Findings will be presented at 
international conferences and published as open access 
articles in high-impact journals. Through targeted 
briefings, we will seek to inform authoritative national, 
European and global developers of clinical guidelines 
including the British Hypertension Society, UK National 
Institute for Health and Care Excellence and NHS 
commissioners and providers locally. We will produce a 
targeted dissemination plan for the public in conjunction 
with the project’s PPI group. We will specifically target 
local patient participation groups and relevant hyperten-
sion charities. We will also plan a public dissemination 
event for patients, clinicians and providers or commis-
sioners on the subject of understanding cardiovascular 
risk, at which these findings will be presented.
The INTERPRESS collaboration will act as an inter-
national forum for clinicians and researchers with an 
interest in IAD and act as a future platform for interna-
tional research activity in this area.
dIscussIon
The results of INTERPRESS IPD meta-analysis will 
inform the practice of clinicians who need to manage a 
patient with an IAD. Our findings will define populations 
with small IADs who can be reassured over this clinical 
finding, and provide the evidence to identify those with 
clinically important IADs who may benefit either indi-
vidually from further cardiovascular investigation or at a 
population level through further research for interven-
tions to mitigate risk. Our results will help clinicians to 
inform patients about their future risk more accurately. 
Patients will benefit individually by being better informed 
about any excess CVD risk based on their interarm BP 
differences.
Although our previous findings have already 
contributed to international clinical guidelines on BP 
measurement,21 28 statements in current versions are still 
largely based on expert opinion rather than evidence. 
INTERPRESS will provide important new evidence that 
will directly inform future updates of international guide-
lines and clinical practice and impact on patient care.
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